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Post-translational modification of
proteins allows for added versatility of
protein function and precision in protein
regulation. The effects of various modifi-
cations such as phosphorylation, acetyla-
tion, and glycosylation have been previ-
ously studied in detail. However, there are
also proteins that function themselves as
the modifying groups of other proteins.
The founding member of this group of
modifier proteins is called ubiquitin, and
we are just beginning to understand the
effects of modification of substrates by
ubiquitin and other ubiquitin-like modi-
fiers. These modifiers have been discov-
ered in many species and are involved in
diverse biochemical pathways. Despite
this diversity, all share similarities to the
ubiquitin system. Every member of this
ubiquitin-like family covalently attaches
to its target substrates via a C-terminal
glycine in the modifier, and the process of
attaching these ubiquitin-like proteins to
their substrates follows a conserved,
multi-step enzymatic pathway.
Ubiquitin remains the best character-
ized member of this family. Like other
family members, ubiquitin is covalently
attached to the ʵ-amino groups of lysines
in its target proteins. Ubiquitin was initial-
ly studied for its involvement in protein
degradation: post-translational addition of
poly-ubiquitin chains to a substrate protein
targets the substrate for degradation by a
large proteolytic machine called the pro-
teasome. However, ubiquitin has multiple
roles in the cell beyond protein degrada-
tion, including protein trafficking, DNA
repair, and various stress responses. How
ubiquitin molecules are linked to one
another in a chain and the length of the
chain can profoundly influence the fate of
the modified protein [1, 2].
In the late 1990s, a mammalian pro-
tein called RanGAP1, a guanine nucleotide
exchange factor that functions in protein
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SUMO (Small Ubiquitin-related Modifier) is a small protein that covalently attaches to a lysine
residue of another protein in a reversible fashion. SUMO attachment to its substrate proteins
causes changes in the localization, activity, or binding partners of the substrate. SUMO has
been shown to play a role in a multitude of processes; these include chromosome segrega-
tion, cell cycle progression, and DNA damage recovery. Defects in the SUMO pathway have
been demonstrated to affect tumorigenesis and the inflammatory response as well as other
human diseases.import into the cell nucleus, was discov-
ered to be post-translationally modified by
a novel protein [3]. This protein turned out
to be related to ubiquitin and was named
“SUMO,” which is short for Small
Ubiquitin-like Modifier. SUMO attach-
ment to proteins is often referred to as
“sumoylation.” Sumoylation of RanGAP1
localizes RanGAP1 to the cytoplasmic side
of nuclear pore complex [4, 5].
Since its discovery on RanGAP1,
SUMO has been found to modify a surpris-
ingly large number of proteins in many dif-
ferent organisms. Although the exact role of
sumoylation for many specific proteins
remains unclear, misregulation of the SUMO
system is likely to contribute to tumorigene-
sis and autoimmune defects as well as other
human diseases.The list of in vivo targets for
SUMO in mammalian cells includes the
tumor suppressor p53 and promyelocytic
leukemia protein, or PML; the PML gene is
involved in chromosomal translocations that
are responsible for certain leukemias [6, 7].
Another SUMO target is Sp100, an autoanti-
gen in primary biliary cirrhosis [7]. IʺBʱ, a
protein inhibitor of the NF-ʺB transcription
factor, is modified by both SUMO and ubiq-
uitin [8]. SUMO has also been shown to
modify a number of transcription factors
including p300 and Sp3 [9, 10].
The biochemical affect of sumoylation
on a substrate protein often remains elu-
sive. For example, only a small pool of the
transcription factor Sp3 is sumoylated at
any given time. However, this minor popu-
lation of modified Sp3 leads to an overall
repression of the transcriptional activity of
Sp3. If sumoylation of Sp3 is abolished
either by a mutation of the protein's accep-
tor lysine, or by expression of the enzyme
that removes SUMO from Sp3, there is a
significant increase in transcriptional acti-
vation by Sp3 [10, 11]. Since only a minor-
ity of the Sp3 protein is sumoylated, the
mechanism that allows for an enhancement
of overall transcriptional activation by Sp3
when the protein's sumoylation is abol-
ished remains a mystery.
Many SUMO targets have been iden-
tified in mammalian cells, but work in
simpler, more genetically tractable organ-
isms has greatly aided our ability to deter-
mine the specific functions of protein
sumoylation. Baker's yeast, or
Saccharomyces cerevisiae, is a favorite
model eukaryote, and studies of the
SUMO system in this yeast have furthered
our understanding of this novel protein
modification system. Smt3 is the SUMO
protein in yeast and its conjugation to an
acceptor protein occurs by a multi-step
pathway, which ultimately leads to an
isopeptide bond between the C-terminal
carboxyl group of the mature Smt3 and the
ʵ-amino group of a lysine side chain of the
target protein. Ulp1, which also acts as a
desumoylating enzyme, cleaves the ATY
tail at Smt3's C-terminus to release a 98-
amino acid mature protein ending in di-
glycine [12]. This mature Smt3 is activat-
ed for conjugation by adenylation when
Uba2/Aos1, the activating enzyme (E1),
attacks the carboxyl-AMPof Smt3 to form
an Uba2-Smt3 thioester. Next, the activat-
ed Smt3 is transferred by E1 to the cys-
teine side chain of Ubc9, the conjugating
enzyme (E2). From there, Smt3 is trans-
ferred to a lysine residue on the acceptor
substrate. This last transfer is often facili-
tated by a protein ligase (E3) functioning
as an adaptor [13], and frequently occurs
at an [I/V] KXE consensus site [10]. Three
currently identified E3s in yeast are Siz1,
Siz2, and Mms21 [14, 15].
In yeast, sumoylation is an essential
process affecting chromosome dynamics as
well as many other processes in the cell. In
1995,Smt3wasisolatedinyeastinanover-
expression screen as a suppressor of a tem-
perature-sensitive Mif2 mutation [16]. The
Mif2 gene encodes a centromere protein
that has homology to the mammalian
CENP-C centromere protein. In two later
studies, Ulp2, an enzyme that removes
Smt3 from its protein substrates, was found
to localize to chromosomes, especially to
rDNA repeats [17], and Smt3 also was
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Furthermore, a temperature-sensitive muta-
tion in Smt3 was identified that causes a
defect in chromosomal segregation [18].
Regulation of Smt3 modification is
important for cell cycle progression.
Strains mutated in enzymes required in
sumoylation (ubc9) and desumoylation
(ulp1) show arrest at the G2/M transition.
∆siz1 ∆siz2 double mutants show a build-
up at G2/M. These phenotypes may result
from a failure to properly segregate chro-
mosomes [12, 14, 19]. In addition the ulp2
null mutant is temperature sensitive and
displays decreased plasmid and chromo-
some stability, a severe sporulation defect;
and hypersensitivity to the DNA-damag-
ing agents hydroxyurea and MMS as well
as to benomyl, a microtubule depolymer-
izing agent [20]. These pleiotropic effects
reinforce the idea that regulation of
sumoylation and desumoylation affects
many processes within the cell, particular-
ly processes related to chromosome
dynamics.
Although the yeast gene encoding
SUMO is required for viability, as are
many of the enzymes involved in its
attachment to and removal from sub-
strates, in the limited number of substrates
that have been characterized the sumoyla-
tion of these substrates is not essential for
viability, indicating that there are molecu-
lar targets of Smt3 whose effect of SUMO
modification is still unknown. The first
sumoylated proteins identified in S. cere-
visiae were a subset of the septins, which
are proteins required for normal bud
growth and cytokinesis. However, in the
absence of sumoylation of the septins,
there is no apparent phenotype in the cells
[14].Ashort list of proteins whose sumoy-
lation has been characterized in yeast
includes topoisomerase II (TopII).
Although the sumoylation of TopII is not
required for its essential function, elimi-
nating the sumoylation results in a change
of cohesive properties of the centromere
[21]. Proliferating cell nuclear antigen
(PCNA) is a sliding clamp for DNA-poly-
merase involved in DNA synthesis and
repair. Sumoylation of PCNA occurs on a
lysine residue, which is also ubiquitinated;
this ubiquitination stimulates the repair
function of PCNA [22]. The sumoylation
of PCNA, which occurs predominately in
S phase, has been shown to create a bind-
ing surface which interacts with Srs2 at
higher levels than non-sumoylated PCNA.
This Srs2-SUMO-PCNA interaction
seems to decrease interchromosomal
recombination rates presumably through a
decrease in recombination of replicating
chromosomes [23]. Sumoylation of anoth-
er subset of additional proteins, which are
either involved in chromosome cohesion;
Pds5 and Ysc4 [24, 25], or DNA repair
proteins Yku70 and Smc5 [15] have been
reported, but the sites of sumoylation are
not yet mapped.
In order to better understand the
importance of the SUMO pathway, a com-
prehensive list of sumoylated proteins
must first be generated. There has been a
recent flurry of proteomic experiments
undertaken to address this question. Since
2004, a number of studies have added to
the list of sumoylated proteins in S. cere-
visiae by identifying Smt3 conjugated pro-
teins through affinity purification of
SUMO-containing proteins. This was fol-
lowed by tandem mass spectrometric iden-
tification of digested peptides from the
purified mixture. The constraints of these
purifications were slightly different in a
number of the screens. Many of the purifi-
cations were done in wild-type yeast under
normal conditions [26-28]. However some
purifications of SUMO-containing pep-
tides were done under stress conditions,
which increased the number of Smt3 con-
jugates [29], and another purification was
conducted from a ulp1 deletion strain.
Ulp1 is one of the two desumoylating
enzymes and this deletion also results in a
higher level of sumoylated proteins [30].
Incorporating the data from these five
purifications results in greater than 100
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overlap between SUMO conjugated pro-
teins found in the various purifications in
general was less than 50 percent. This sug-
gests that separate purifications were iden-
tifying specific subsets of proteins and
also that there is a high likelihood that
some of the identified SUMO-interacting
proteins are not true substrates of Smt3,
but possible contaminating proteins. Now
that a comprehensive list of sumoylated
proteins in S. cerevisiae is being compiled,
the next challenge is understanding the
importance of sumoylation on these spe-
cific substrates.
Sumoylation has been shown to be
involved in cell cycle regulation, DNA
repair, and chromosomal maintenance.
The yeast model has been beneficial in
studying the role of sumoylation in these
cellular processes, however SUMO is also
implicated to play a role in a number of
diseases that are only found in higher
eukaryotes. These include diabetes,
promyelocytic leukemias, and neurode-
generative diseases to name a few. The
precise role of SUMO in these diseases is,
for the most part, unclear. As an example
of the type of research being done on
SUMO the following is a summary of
recent evidence that sumoylation con-
tributes to Huntington's disease.
Huntington's disease is characterized by
the accumulation of a pathogenic protein,
Huntingtin (Htt). Using a Drosophila
model system, a fragment of the Htt pro-
tein was found to be modified by both
SUMO and ubiquitin. When a mutant Htt
was expressed throughout the fly, the level
of neurodegeneration was found to be far
more severe in flies with wild-type levels
of SUMO as opposed to those flies, which
had lowered sumoylation activity. In con-
trast, lowering the levels of ubiquitination
activity aggravates the disease [31]. This
is just one of the many examples of
SUMO’s role in disease. Sumoylation has
been shown to affect a wide range of bio-
logical processes from yeast to humans.
Future studies on the regulation of SUMO
modification as well as the physiological
affect of its modification on various sub-
strate proteins will certainly continue to
make this an exciting and diverse field.
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